Tacrilimus common name FK506 has
- The therapeutic range is narrow, so Ctrough concentrations (C0, Ctrough) are recommended to monitor concentrations and adjust daily dose;
- CYP3A5 genotype affects the rate of metabolism of Tacrolimus;
- Reaching the Ctrough target early reduces the risk of acute rejection for patients in the first 3 months: 8-12 ng/ml or 5-10 ng/ml depending on the transplant center.
In the world, there are many studies demonstrating that CYP3A5 genotyping in order to determine the dose of Tacrolimus after transplantation without taking time to detect the dose early to achieve C0 concentration and to limit the risk of acute rejection in the first 15 days, increase the success of the post-transplant, reduce the side effects of the drug.
+ The international guideline of the CPIC association regulates the metabolic rate of the CYP3A5 genotype and the direction of dose adjustment of TAC for CYP3A5 expressor, CYP3A5 non-expressor.
Sample used: The sample used for the test is 1 - 3 ml of whole blood contained in an EDTA anticoagulation tube
Technology used: Sequencing region carrying variant on CYP3A5 gene by PCR technique on automatic gene sequencing system ABI3130xl (USA)
Time to return results: from 3 days